In summary, these data show that selective inhibition of the PDGF-CC/PDGFRα signaling pathway resulted in a reduction in stroke infarct volume and myofibroblast expansion similar to that seen with imatinib treatment, thus potentially offering a targeted treatment approach for patients with ischemic stroke. This evidence concerns the gene CXCR1 and ischemic stroke.